Objective. Osteoarthritis (OA) is one of the leading causes of disability within the adult population. Currently, its diagnosis is mainly based on clinical examination and standard radiography. To date, there is no way to detect the disease at a molecular level, before the appearance of structural changes and symptoms. So an attractive alternative for monitoring OA is the measurement of biochemical markers in blood, urine, or synovial fluid, which could reflect metabolic changes in joint tissue and therefore disease onset and progression. Animal models are relevant to investigate the early stage of OA and metabolic changes occurring in joint tissues. The goal of this narrative review is to summarize the scientific data available in the literature on soluble biomarkers in animal models of OA. Design. A literature search was conducted using the PubMed/ Medline and Scopus databases between February 1995 and December 2015. All original articles, systematic and narrative reviews published in French or in English were considered. Results. We summarized the data of 69 studies and proposed a classification scheme for OA biomarkers in animal studies, largely inspired by the BIPEDS classification. Conclusions. Studies about biomarkers and animal models indicate that some markers could be valuable to monitor OA progression and assess therapeutic response in some animal models.
Introduction
Osteoarthritis (OA), a disease of the entire joint, is characterized by, synovial inflammation, ligament hyperlaxity, and abnormal subchondral bone remodeling. Currently, its diagnosis is mainly based on radiographic criteria (e.g., joint space width) and clinical symptoms (e.g., pain and loss of function). 1, 2 However, a diagnosis of the disease at a preradiographic stage, when the first molecular changes occur in joint tissues, would be helpful for a better management of the disease. In this purpose, imaging techniques such as ultrasound and magnetic resonance imaging (MRI) have been developed, but their use is limited by their cost and availability. An alternative is the measurement of soluble biomarkers in biological fluids, not only to early diagnose but also to predict the progression of the disease and to assess the effectiveness of treatments. 2 Furthermore, soluble biomarkers can be used as "drug development tools" at preclinical stages and throughout clinical development in phase I to IV trials. 3 At the preclinical phases, the 3 major applications of biomarkers are their use in toxicology studies, in the selection of appropriate animal models and lead compounds and in the identification of the mechanisms of action of an intervention.
In 2006, the BIPED classification was created with the aim of providing a common framework for communication in the field. 1 The acronym "BIPED" stands for Burden of disease, Investigate, Prognostic, Efficacy of intervention, and Diagnostic. The "BIPED" classification was subsequently revised to "BIPEDS," including "Safety." Many reviews on biochemical markers using the BIPEDS classification have been published. 2, [4] [5] [6] In those reviews, biomarkers have been classified based on data coming from human clinical trials. These soluble biomarkers have never been classified based on information coming from animal studies, although animal models are valuable to validate biomarkers.
Currently, several animal models of OA in rabbits, dogs, rats, mice, guinea pigs, horses are conventionally used, mainly to test therapeutic modalities. Three general categories exist for in vivo OA models: spontaneously occurring OA (including genetically modified animals), mechanically induced accelerated OA by surgery-(e.g., anterior cruciate ligament transection [ACLT]), trauma-, or fracture-induced posttraumatic OA, 7, 8 and chemically induced OA by intraarticular injection of chondrotoxic (e.g., iodoacetic acid), pro-inflammatory (e.g., interleukin-1β [IL-1β]), or catabolic (e.g., matrix metalloproteinase [MMP]) substances. [9] [10] [11] The goal of this narrative review was to synthesize scientific literature on soluble biomarkers measured in biological fluids in different animal models of OA and to classify these biomarkers according the BIPEDS classification.
Methods
The literature search was performed using the PubMed/ Medline and Scopus databases between February 1995 and December 2015. Searches were performed using the search terms "biomarkers," "osteoarthritis," and "animal model." The following word association was used in Medline: ["Biomarkers" OR "Markers"] AND ["Osteoarthritis"] AND ["Animal model"]. In the Scopus database, the code TITLE-ABS-KEY, a combined field that searches article titles, abstracts, and keywords was used. The following words association was used: biomarkers and osteoarthritis and animal model. All original papers, systematic and narrative reviews published in French or in English between February 1995 and December 2015 were included.
The first author (C.B.L.) selected the articles on the basis of the title and abstract and then assessed whether the study met the inclusion criteria. Then the full article was retrieved. The flow diagram for selection of studies is presented in Figure 1 . Data are shown according to the species. By this way, the knowledge on biomarkers in a particular model is summarized. This approach was considered as useful for researchers using that particular model. Thereafter, we propose a classification of these biomarkers according their ability to predict the progression of the disease, to monitor the effect of a treatment or to assess the severity of OA lesions. The classification was performed based on the following definitions: 
Results

Rabbits
In rabbits, a variety of surgical procedures on menisci and ligaments were described to induce knee joint laxity, and subsequently abnormal mechanical strain. These surgical procedures included cruciate ligament transection, with or without medial and collateral ligament section, total or partial meniscectomy, and creation of bucket-handled tears of the meniscus. Prostaglandin (PG) E2 and C-reactive protein (CRP) serum levels were significantly increased 6 weeks after ACLT. 12 In contrast, no significant differences between the pre-ACLT and the post-ACLT values of serum keratan sulfate (KS), hyaluronic acid (HA), and chondroitin sulfate (CS) 846 epitope were observed. 13 However, a significant correlation between histological score and post-ACLT HA concentration was found for the medial femoral condyle. In contrast, thrombin-cleaved osteopontin (OPN) levels in synovial fluid progressively and significantly increased after posterior cruciate ligament transection (PCLT) to reach a maximum after 4 weeks.
14 A positive significant correlation was found between thrombin-cleaved OPN synovial fluid levels and the macroscopic and histological scores.
14 In a longitudinal study, Duclos et al. 15 followed the evolution of serum C-telopeptide of type II collagen (CTX-II) concentration in adult (10-month-old) and growing animals (2-month-old) after ACLT. CTX-II was significantly higher in ACLT-adult rabbits than nonoperated adult animals, while in young animals CTX-II was similar in both groups. In adult ACLT-rabbits, the CTX-II evolution showed 2 distinct elevations, one during the 3 first weeks after surgery, followed by a decreased until the fourth week, and a second peak at the twelfth week. In young animals, CTX-II levels increased rapidly and reached a maximum at week 2 and then, decreased over time until the week 20. 15 In experimental OA induced by anterior and posterior cruciate ligaments transection and medial meniscus excision, Zuo et al. 16 investigated the evolution of serum bone morphogenetic protein-2 (BMP-2), CTX-II, and cartilage oligomeric protein (COMP). The BMP-2 levels were increased at various times after surgery, and significant differences were observed between the OA and the control groups. CTX-II levels were significantly elevated at different intervals after surgery. Significant differences in the COMP levels from W2 to W20 were observed between the OA and the control groups. 16 Another research observed a significant increase of CTX-II in synovial fluid in rabbit with medial meniscectomy. 17 Moreover, highly significant correlations between synovial fluid CTX-II levels and the macroscopic and microscopic scoring results were found.
Rats
In rats, a variety of experimental OA model exist. The most commonly used rat OA model is the surgically induced medial meniscal tear (MMT), ACLT alone or in combination with (partial) medial meniscectomy (ACLT + pMMx). 18 Intra-articular monoiodoacetate (MIA) injection is also frequently used. Ovariectomy in rats was proposed to mimic postmenopausal OA in humans. 19 In ACLT model, serum level of C2C, a biomarker of type II collagen degradation, was decreased by moderate running on a motorized treadmill (at a speed of 18 m/min for 30 min/d, 3 days per week) while the serum level of CPII, a biomarker of type II synthesis, was decreased by intense running (at a speed of 18 m/min for 60 min/d, 3 d/wk) 2 and 4 weeks after surgery. 20 In addition, in all the groups at 2 and 4 weeks after surgery, the Osteoarthritis Research Society International (OARSI) histological score was slightly but significantly correlated positively with the C2C/ CPII ratios. 15 In ACLT rats, serum CTX-II and COMP levels were increased and only CTX-II correlated with the modified Mankin score. 21 In ACLT and MMX rat model, low-intensity pulsed ultrasound (LIPUS) does not affect the degradation of type II collagen at 7 and 14 days after the operation. In contrast, after 28 days, CPII was significantly increased in LIPUS group compared to control group. 22 The oral administration of high dose of glucosamine hydrochloride (1000 mg/kg/d for 56 days) prevented the increase of CTX-II serum levels 23 and high dose of alendronate (ALN), a potent inhibitor of osteoclastic bone resorption, significantly decreased serum levels of COMP in rats with ACLT-induced OA. 24 Another study investigated the effects of physical exercise in healthy young, adult, and aged rats on the expression of lubricin. As expected, the results showed that lubricin levels in rat synovial fluid were decreased with aging. 25 In ACLT/pMMX rat model, treatment of OA rat knees with pharmacologic inhibitors of transforming growth factor-α (TGF-α) (AG1478) and CCL2 (RS504393) signaling pathway, significantly increased serum CPII levels but only AG1478 significantly reduced serum C2C levels and the C2C/CPII ratio compared with untreated OA rats. This finding suggested that TGF-α/CCL2 is an important promoter of articular cartilage degradation in posttraumatic OA. 26 In another study, oral administration of a high dose of BIS076 (245 mg/kg), a natural porcine cartilage extract associated with hydroxyapatite and vitamin D 3 , reduced serum levels of CTX-II and COMP, as well as MMP-3 in OVX and ACLT rats. 27 In ovariectomized (OVX) rats, serum COMP level was decreased by a combination of estrogen and progesterone hormones 10 weeks after OVX surgery. 28 In another study, CTX-II was also increased in the OVX rats compared with the sham-operated group. 19 Several inflammatory mediators were investigated in MIA-induced OA in rats. Orita et al. 29 showed a significant increase in the concentrations of tumor necrosis factor-α (TNF-α) and interleukine-6 (IL-6) starting on day 1 after the injection which reached a maximum at day 4, and thereafter, gradually decreased as the post injection period progressed. The concentration of nerve growth factor (NGF) was significantly increased 1 week after the injection. 29 In 2010, Swearingen et al. 30 showed a time-dependent increase in the release of aggrecanase-cleaved aggrecan (NITEGE and ARGS neoepitopes) into the synovial fluid of the MIA OA knee joints.
These results were consistent with those of Dufield et al., 15 showing that the levels of aggrecan neoepitopes ARGS and AGEG were elevated in the synovial fluid of rat knee after intraarticular (IA) injection of TNF-α. 31 Moreover, synovial fluid ARGS levels increased following surgically induced joint instability in the rat meniscal tear (MT) model.
In a MIA-induced OA model in rats, serum glycosaminoglycan (GAG) levels significantly decreased after administration of diacetylrhein. 33 Rats with arthritis induced by Freund's complete adjuvant (FCA) showed elevated levels of synovial fluid IL-1β, IL-6, and TNF compared with the control group. In MIA rat model, a biphasic elevation of synovial fluid concentration of monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein-3α (MIP-3α), and IL-6 were observed. 34 
Mice
In STR/ort mice, serum level of MMP-3 increased from week 7 to 9. 35 In addition, high levels of urinary CTX-II were observed in the STR OA subgroup compared with the STR non-OA. 36 In a study that compared wild-type (WT) and biglycan/fibromodulin double-deficient mice, the mean serum concentrations of C2C and Coll2-1 were higher in biglycan/fibromodulin double-deficient mice than in the WT mice at all time points. Mean serum concentrations of Coll2-1NO 2 increased progressively with age in WT mice but not in biglycan/fibromodulin double-deficient mice. 37 In mice subjected to noninvasive ACL rupture via tibial compression, serum level of CTX-I was increased in injured mice at all time points compared to uninjured mice. In contrast, serum procollagen type 1 N-terminal propeptide (P1NP) levels were not found to be significantly different between any of the experimental groups at any time points. 8 COMP, MMP-3, and MMP-9 synovial fluid levels also increased in mice after acute joint injury induced by intraarticular fracture. 38, 39 In a study of Porta et al., 40 the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) did not modify serum levels of MIA and control groups.
Other studies examined the involvement of inflammatory and oxidative stress biomarkers in the pathogenesis of OA. They demonstrated an increase in serum levels of IL-6, IL-1β, and TNF-α both in STR/ort mice and in a model of intra-articular fracture. 41, 42 In obese and hyperlipidemic STR mice, serum levels of malondialdehyde (MDA), CTX-II and CPII were elevated compared with levels in the control CBA mice. 43 Notably, the level of MDA was correlated with that of CTX-II, but not of CPII.
Guinea Pigs
The Dunkin-Hartley guinea pig strain displays a spontaneous onset of progressive degenerative changes in the knee joints that mimics the pathophysiological processes observed in primary human OA. 44, 45 KS and COMP levels were elevated in the knees of Hartley (OA-prone) compared with the strain 13 (OA-resistant) animals after 2 months of age. 45, 46 Moreover, synovial fluid concentration of KS and COMP correlated positively with the severity of histological damage in both strains. 46 In addition, the levels of serum C2C/CPII, representing the ratio of type II collagen degradation and synthesis, were elevated in the OA-prone Hartley compared with strain 13 animal after 4 months of age. 46, 47 Huebner et al. 47 observed abnormalities in collagen network beginning at 2 months of age. Among CTX-II, Coll2-1, and C2C, only serum Coll2-1 increased coincidentally with the appearance of the early disruption of the collagen fibril and correlated with histological severity. 47 In DunkinHartley guinea pig with ACLT, C2C, stromal cell-derived factor (SDF-1), GAG, MMP-13, and IL-1β were elevated in the synovial fluid compared with the control group. 48 Significant positive correlations were found between the SDF-1, GAG, and C2C synovial fluid concentrations and the Mankin score. Huebner et al. 46, 49 showed that the Hartley strain exemplified a serum/chemokine profile indicative of a pro-inflammatory state compared with Strain 13. Among the cytokines and chemokines elevated in the Hartley strain, they found IL-6, IL-17, IL-8, and TNF-α. In other research, they also demonstrated that transglutaminase isoenzyme 2 (TG2) concentrations were correlated with synovial fluid COMP. 50 In another study, dietary omega-3 (n-3) polyunsaturated fatty acid (PUFA) reduced OA in the OA-prone DunkinHartley compared with OA-resistant Bristol Strain1-2 (BS2). 51 McDougall et al. 52 showed that urine concentrations of CTX-II were reduced by cathepsin K inhibitor. Horcajada et al. 44 compared the effects of 3 polyphenols oleuropein, rutin, and curcumin on joint ageing and OA development. Coll2-1 was decreased by rutin and the combination of rutin/curcumin. Fib3-1 and Fib3-2 (2 specific peptides of fibulin-3) were only decreased by the rutin/curcumin mixture, while Coll2-1NO 2 was significantly decreased by all treatments. Moreover, Coll2-1NO 2 , Fib3-1, and Fib3-2 were correlated with histological global OA score while Coll2-1NO 2 and Fib3-2 also correlated with synovial histological score. 44 In a study of metabolic fingerprints, Lamers et al. 53 showed that purine metabolism is of major importance in OA.
Dogs
In canines, synovial fluid CTX-II levels were elevated early after unilateral cruciate ligament transection. 54 Coll2-1 and Coll2-1NO 2 also appeared to be OA biomarkers of early structural changes. Indeed, following ACL transection, a significant and rapid increase (2 weeks and 6 weeks, respectively) of these markers was observed in serum. 55 Moreover, a positive and highly significant correlation was found between Coll2-1 concentrations and the global macroscopic score. Coll2-1NO 2 concentrations were found to be significantly and positively correlated with the size of the osteophytes. 55 The ratio Coll2-1NO 2 /Coll2-1 was negatively correlated with macroscopic parameters and the histological score, but not with the osteophyte size.
In beagle dogs subjected to cranial cruciate ligament transection (CrCLt), synovial fluid levels of AGEG neoepitope were significantly elevated compared with either contralateral knee or contralateral knee in sham-operated animals. 31 In a canine model of posttraumatic OA, serum level of KS and HA rise between 1 to 3 weeks after ACLT. 56 In ACLT dog model, tenascin-C (TN-C), an extracellular matrix glycoprotein, increased in synovial fluid 1 month after ACLT compared with the control group. 57 In dogs undergoing CrCLt, bone specific alkaline phosphatase (BAP) activity increased in synovial fluid with time after transection and zoledronic acid (25 µg/kg) partially inhibited this change. Synovial fluid C1,2C, CS, and serum CPII levels were significantly increased after transection. Zoledronic had no effects on these biomarkers. Interestingly, significant correlations were detected between synovial fluid BAP activity, serum CPII concentration and synovial fluid CS concentration and radiographic findings when all groups were combined. 58 In a study published in 2009, Connor et al. 59 showed that a cathepsin K inhibitor (SB-553484) reduced the levels of urinary CTX-I and CTX-II in mature female beagle dogs with partial medial meniscectomy. PF152, a novel highly selective MMP-13 inhibitor, reduced joint lesions in adult dogs with OA induced by partial MMx and decreased biomarkers of type II collagen neoepitope (TIINE) and aggrecan (neoepitopes ARGN or AGEG) degradation. 60 In another study, high dose of vitamin E (400 UI/animal/day) administrated orally in OA dogs with CrCL transection, reduced inflammation markers including NO x , IL-1β, and PGE 2 in synovial fluid. 61 During the progression of OA induced by a surgically created medial patellar luxation (MPL) in the left stifle of dog, synovial fluid and serum TIMP-2 levels were significantly decreased, whereas MMP-2 in synovial fluid was significantly increased. 62 In dogs referred to the clinic, synovial fluid TIMP-1 level was increased in dogs with ACL rupture (ACLR), osteochondritis dissecans (OCD), fragmented coronoid process (FPC), and hip dysplasia (HD) compared to dogs without musculoskeletal diseases. 63 Carprofen (2.2 and 4.4 mg/kg), a nonsteroidal inflammatory drug, had no effect on MMP activity in ACLT-induced OA dogs. 64 Synovial fluid PGE 2 levels were dose-dependently diminished by celecoxib in beagle dog OA induced in one knee according to the groove model showing a neutral effect of celecoxib on the characteristics of experimentally induced OA in vivo. 65 In 2013, Gharbi et al. 66 provided a proteome mapping of dog serum after ACLT surgery. A number of proteins, such as fetuin B and complement C3, were increased in dog OA serum whereas others, such as hyaluronan binding protein 2, complement C1s and C4 were decreased. 66 Another study investigated the effects of total MMx on biomarkers in synovial lavage fluid. COMP and KS were significantly increased. 67 Serum levels of COMP and urinary levels of CTX-II were also increased after a joint bleed mimicked by injecting freshly collected (vena puncture) autologous blood intra-articularly in the knee. 68 Another research observed that a subcutaneous injection of calcitonin (3 units per kg of body weight) significantly decreased the urinary excretion of D-pyridinoline (D-Pyr) and blood levels of KS and HA in dogs after ACLT. 69 
Horses
The published studies investigated the effect of exercises on OA incidence and progression. A study showed that the subchondral bone lysis on standard X-ray was strongly correlated with CPII, and that subchondral bone proliferation at the joint capsule attachment was strongly correlated with PGE 2 . 70 In addition, radial carpal bone edema detected using MRI correlated well with C1,2C increase in the synovial fluid. Synovial fluid levels of Coll2-1 were significantly elevated in tarsocrural joints affected with osteochondrosis compared with unaffected joints. 71, 72 Another study compared sera of box-stall rest, pasture and trained foals. 73 Lower serum levels of CPII and higher levels of CTX-I were found in the trained foals compared with the other groups. It was noticed that serum levels of CTX-I and CPII significantly increased with age in all groups. 73 In another study, exercise induced a significant increase in the synovial fluid CPII, GAG, C1C, C2C, CTX1 concentrations. 74 Finally, Fuller et al. 75 in 2010 demonstrated that levels of synovial fluid BAP were significantly higher in the clinically active joint than in the contralateral joint, while KS, GAG, and HA were significantly lower in OA than in the contralateral joint. These biomarkers also showed good correlation with arthroscopy score of cartilage damage.
In an equine metacarpophalangeal groove model, Manninchedda et al. 76 showed that synovial fluid levels of C2C, COMP, CTX-I, osteocalcin (OC), and CS-846 were not significantly different between groups. 76 
Sheep
In sheep undergoing meniscal destabilization (MD), increased levels of dimethyl sulfone (DMSO 2 ) were observed in serum after 4 weeks by nuclear magnetic resonance spectroscopy, while in ACLT-induced OA sheep, an increase of 3-methylhistidine and a decrease of branched chain amino acids, comprising the essential amino acids valine, leucine, and isoleucine (BCAAs) were identified. 77 In another study, synovial fluid of MMP-2 was detected 2 and 4 weeks postoperatively in a temporomandibular joint (TMJ) model of OA in sheep. 78 Moreover, MMP-2 activity correlated with initial articular cartilage destruction rather than with the progression of OA. In sheep responses to ACL reconstruction injury, a metabolic profiling of synovial fluid identified 6 metabolites such as isobutyrate, glucose, hydroxyproline, asparagine, serine, and uridine, which could be suggested as biomarkers for early postinjury degenerative changes in the knee joints. 79 
Discussion
We have attempted to gather all animal studies in English and French published between 1995 and 2015 and investigating soluble biomarkers in OA. A summary is available in Table 1 . We also proposed a classification scheme for these biomarkers, largely inspired of the BIPEDS classification ( Table 1) .
In all animal studies that we have selected, soluble biomarkers are viewed as useful indicators of joint tissue metabolism, particularly of bone and cartilage. Some of them are well correlated with histological lesion severity, and can be considered as a burden of disease biomarkers, but none of them can be classified in the prognostic and safety categories. 10 One major concern in animal studies is the method to harvest synovial fluid. Although the collection of synovial fluid in animal models can be challenging, synovial fluid offers the most proximal source for joint turnover information. 80 The majority of studies in animals have utilized the technique of joint lavage. However, other methods exist for collecting specimens depending on the animal size. In small animal like mice, rats or guinea pigs, Whatman paper can be used to absorb synovial fluid. 39 Recently, Seifer et al. 39 described a method for synovial fluid recovery using Melgisorb (Tendra, Sweden), a calcium sodium alginate compound (CSAC), used as a dressing on wounds to absorb heavy exudate. In dogs, joint lavage with saline has been used to collect synovial fluid and the dilution effect of the lavage has been corrected by normalization to serum urea. 80 Another concern is the age of animals used and the presence or not of cartilage growth plate. In fact, some of the studies reported in this review were conducted in young immature animals, meaning that biomarker levels can be confounded by the presence of growth plate. This should be keep in mind when interpreting results.
Burden of Disease Biomarkers
Numerous biomarkers measured in serum or synovial fluids were correlated with histologic or macroscopic cartilage lesions severity score in different species like rat, mouse, dog, or guinea pig. Interestingly, some of them increased rapidly after the onset of the disease, before the appearance of the histological structural changes. Most particularly, Coll2-1 is particularly precocious. In serum of guinea pig, Coll2-1 increase was coincident with the early disruption of the collagen fibril visible by birefringence before the appearance of structural changes observable by conventional microscopy. This finding suggests that the Coll2-1 biomarker may be an early indicator of the onset of chondropathy in the guinea pig. 47 This also means that biomarkers of type II collagen degradation could be considered as surrogate biomarkers of histology in animal study. This could be advantageous for studying the kinetic of drug candidate efficacy and reduce the number of euthanized animals.
Prognostic Biomarkers
Demonstrating the prognostic value of biomarkers in animal models remains very challenging because in most models, OA is induced using well-standardized methods and lesion progression is predictable and homogenous. To be recognized as a prognostic biomarker, a biomarker has to predict the incidence or the progression of the disease. To our knowledge, there is no biomarker that can be classified in this category based on animal study. This would require a prospective study including pets with OA risk factors and different disease progression rate. This type of information could be helpful for the daily management of care in pets.
Efficacy of Intervention
Soluble biomarkers have been largely used as drug development tools in OA. Not exhaustively, we can mention in rats, diacetylrhein that reduces serum GAG levels, 33 oral glucosamine hydrochloride that prevents the increase of CTX-II levels 23 and alendronate, a potent inhibitor of osteoclastic bone resorption that decreases serum levels of COMP. 24 In guinea pigs, prolonged (1 month) administration of cathepsin K inhibitor reduces uCTX-II excretion and oleuropein decreases Coll2-1. 44, 52 In dogs, cathepsin K decreases urinary CTX-I and CTX-II 59 and PF152 reduces TIINE and aggrecan (neoepitopes ARGN or AGEG). 60 Another study in dogs with OA using a supplement with a high dose of vitamin E showed a reduction in inflammation joint markers such as PGE 2 and IL-1β. 61 These findings indicate that a large panel of biomarkers should be used in the preclinical phase of drugs or other intervention development. This approach would allow a better understanding of their mechanisms of action but also the early detection of potential safety issues, and hence could enhance the drug development efficiency, and possibly reduce the overall cost of OA clinical trial. This also allows the selection of one or more biomarkers sensitive to drug activity that can be used in the next phases of drugs development. For these reasons, the US Food and Drug Administration (FDA), the Osteoarthritis Research Society International (OARSI) and European Medicine Agency (EMA), recently published guidelines recommending a higher level of integration of biomarkers MCP-1 = monocyte chemoattractant protein 1; MIP-3α = macrophage inflammatory protein 3α; s = serum; sf = synovial fluid; u = urine; AEA = endocannabinoids anandamide; 2-AG = 2-arachidonoylglycerol; ARGS neoepitopes = aggrecan peptide ending in ARGS; BAP = bone-specific alkaline phosphatase; BCAAs = branched chain amino acids; BMP-2 = bone morphogenetic protein 2; C1,2C = type I and II collagen degradation fragments; C1-2-3C = complement C1-2-3C; C2C = type II collagen cleavage product; Coll2-1 = Sequence of 9 amino acids derived from the α-helix of type II collagen; Coll2-1 NO2 = peptide of 9 amino acids nitrated on its tyrosine residue specific for the type II collagen α-1 chain; COMP = cartilage oligomeric protein; CPII = carboxyl propeptide of type II pro-collagen; CRP = C reactive protein; CS = chondroitin sulfate; CTX-I = C-terminal telopeptide of collagen type I; CTX-II = C-terminal telopeptide of collagen type II; Fib3-1 = Fibuline 3-1; Fib3-2 = Fibuline 3-2; GAG = glycosaminoglycan; HA = hyaluronic acid; IL-1β = interleukin 1-beta; IL-6 = interleukin 6; IL-8 = interleukin 8; IL-17 = interleukin 17; KS = keratan sulfate; MCP-1 = monocyte chemoattractant protein 1; MDA = malondialdehyde (an oxidative stress marker); MIP-3α = macrophage inflammatory protein 3α; MMP-3 = matrix metalloproteinase-3; MMP-13 = matrix metalloproteinase-13; MMP-9 = matrix metalloproteinase-9; NGF = nerve growth factor NITEGE = aggrecanase cleaved aggrecan; NMR, nuclear magnetic resonance; 3-NT = 3-nitrotyrosine; OC = osteocalcin; OPN = osteopontin; PGE2 = prostaglandin E2; P1NP = procollagen type 1 N-terminal propeptide; n-3 PUFA = omega-3 polyunsaturated fatty acid; TN-C = tenascin-C; SDF-1 = stromal cell-derived factor 1; TG-2 = transglutaminase isoenzyme 2; TIMP-1 = tissue inhibitor of matrix metalloproteinase-1; TIMP-2 = tissue inhibitor of matrix metalloproteinase-2; TNF = tumor necrosis factor. in the development and testing of new drugs to advance decision making on dosing, time and treatment effect, trial design, and risk/benefit analysis. 3 
Diagnostic Biomarkers
Diagnostic biomarkers ideally differentiate animals with and without the disease. At this time, in guinea pigs, only the ratio C2C/CPII, reflecting type II collagen turnover, have been demonstrated to discriminate OA-prone Hartley and strain 13 animals, a strain that does not develop OA. 46 This ratio was higher in OA-prone Hartley strain guinea pigs compared to OA-resistant strain 13, indicating an upregulation of collagen degradation in the absence of a compensatory upregulation in collagen synthesis between 2 and 12 months of age. 46 In mice, several biomarkers discriminate different mouse strain. Serum levels of MDA, CTX-II and CPII were elevated in obese and hyperlipidemic STR/ORT (STR) mice compared with control CBA mice. 43 Together, these observations suggest that oxidative stress is associated with the development of OA, possibly via the degradation of type II collagen. 43 In parallel, high levels of urinary CTX-II were found in the STR OA subgroup compared with the STR non-OA. 36 The models are very relevant to validate biomarker and assess their capacity to discriminate diseased and nondiseased animals.
Safety Biomarkers
In 2011, the BIPED classification was expanded and a "Safety" category to the BIPED system was added. 81 Safety biomarkers could be used in preclinical and clinical applications to monitor the health of the joint tissues, the whole joint organ, or the skeleton in general. 81 For instance, biomarkers reflecting the synthesis of the main proteins of the joint might provide an index of the "joint-protective" effect of a potential treatment. 81 Currently, there are no studies exploring specifically this aspect of joint tissue related biomarkers. A case in point could be evaluation of fibrosis markers in animals treated with MMP inhibitors.
Conclusion
In conclusion, this systematic review indicates that some markers could be valuable to evaluate the burden of OA disease and to assess the therapeutic response in animal models. The most investigated biomarkers in terms of burden of disease assessment are those derived from type II collagen metabolism. Since OA represents a process of matrix damage, turnover, and attempted repair, the use of multiple biomarkers, both anabolic and catabolic, could likely be most accurate in characterizing OA. 11 Finally, soluble biomarkers can be a useful "drug development tools" that should be early integrated in the research program of new drugs. As previously mentioned, biomarkers may be helpful to assess drug safety, to assist with selection of animal models and lead compounds and assess drug mechanisms of action. 3 Furthermore, the use of biomarkers at the preclinical stages is helpful to select the doses and the route of administration, to evaluate the residency time in joint, to select a companion biomarker for the next clinical phases and the personalized management of OA, to provide insights into disease pathophysiology and to provide confidence in histological assessment (when synovial fluid markers know to correlate with histology provide consistent results with histology in a subsequent study).
